MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
0.2010
-0.0071
-3.41%
After Hours: 0.2001 -0.0009 -0.45% 19:24 03/30 EDT
OPEN
0.2116
PREV CLOSE
0.2081
HIGH
0.2116
LOW
0.1893
VOLUME
4.62M
TURNOVER
--
52 WEEK HIGH
3.390
52 WEEK LOW
0.1611
MARKET CAP
21.03M
P/E (TTM)
-0.0741
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OTLK last week (0323-0327)?
Weekly Report · 21h ago
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants
TipRanks · 5d ago
Outlook Therapeutics closes $5.0 million public offering; warrants target up to $5.0 million additional proceeds
Reuters · 5d ago
OUTLOOK THERAPEUTICS ANNOUNCES CLOSING OF $5.0 MILLION PUBLIC OFFERING
Reuters · 5d ago
Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Dow Jones · 5d ago
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Barchart · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-FedEx, Estee Lauder, Janus Henderson
Reuters · 6d ago
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.